|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0003250,
umls-concept:C0008109,
umls-concept:C0022646,
umls-concept:C0035015,
umls-concept:C0041703,
umls-concept:C0178539,
umls-concept:C0205178,
umls-concept:C0301630,
umls-concept:C0332293,
umls-concept:C0450127,
umls-concept:C0676831,
umls-concept:C0723325,
umls-concept:C1257890,
umls-concept:C1548437,
umls-concept:C1709854,
umls-concept:C1882923,
umls-concept:C2603343,
umls-concept:C2745955
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
1999-3-11
|
|
pubmed:abstractText |
A double-blind, placebo-controlled phase III study was performed to assess whether basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody, reduced the incidence of acute rejection episodes in renal allograft recipients.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
0041-1337
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
27
|
|
pubmed:volume |
67
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
276-84
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:10075594-Acute Disease,
pubmed-meshheading:10075594-Adult,
pubmed-meshheading:10075594-Antibodies, Monoclonal,
pubmed-meshheading:10075594-Cause of Death,
pubmed-meshheading:10075594-Creatinine,
pubmed-meshheading:10075594-Double-Blind Method,
pubmed-meshheading:10075594-Female,
pubmed-meshheading:10075594-Follow-Up Studies,
pubmed-meshheading:10075594-Graft Rejection,
pubmed-meshheading:10075594-Humans,
pubmed-meshheading:10075594-Immunosuppressive Agents,
pubmed-meshheading:10075594-Incidence,
pubmed-meshheading:10075594-Kidney Transplantation,
pubmed-meshheading:10075594-Male,
pubmed-meshheading:10075594-Middle Aged,
pubmed-meshheading:10075594-Postoperative Complications,
pubmed-meshheading:10075594-Receptors, Interleukin-2,
pubmed-meshheading:10075594-Recombinant Fusion Proteins,
pubmed-meshheading:10075594-Time Factors
|
|
pubmed:year |
1999
|
|
pubmed:articleTitle |
Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2-receptor monoclonal antibody. United States Simulect Renal Study Group.
|
|
pubmed:affiliation |
Division of Immunology and Organ Transplantation, University of Texas Medical School, Houston 77030, USA.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study,
Clinical Trial, Phase III
|
